A big obstacle for obtaining factual data on the influence of tyrosine kinase inhibitors on a concurrent therapy is that once an agent has been approved and introduced to the market, it is difficult to find the means for additional drug trials

مهمان عزیز شما حق دیدن لینک ها را ندارید برای استفاده از امکانات کامل انجمن عضو شوید

عضویت